References of "McClung, M"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailDenosumab for the treatment of men with low bone mineral density: 24-month results from the Adamo Trial
Langdahl, B; Teglbjaerg, C; Ho, PR et al

in Endocrine Reviews (2014), 35(3), 22-1

Detailed reference viewed: 11 (1 ULg)
Full Text
Peer Reviewed
See detailInhibition of sclerostin with romosozumab in postmenopausal women with low BMD : phase 2 trial results
McClung, M; Grauer, A; Boonen, S et al

in Osteoporosis International (2013), 24(1), 38-39

Detailed reference viewed: 95 (3 ULg)
Full Text
Peer Reviewed
See detailArzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women.
Cummings, S. R.; McClung, M.; Reginster, Jean-Yves ULg et al

in Journal of Bone and Mineral Research (2011), 26(2), 397-404

BACKGROUND: Arzoxifene is a selective estrogen receptor modulator (SERM) more potent in preclinical testing than currently available agents. Its effects on clinical outcomes are not known. METHODS: In a ... [more ▼]

BACKGROUND: Arzoxifene is a selective estrogen receptor modulator (SERM) more potent in preclinical testing than currently available agents. Its effects on clinical outcomes are not known. METHODS: In a randomized blinded trial, women age 60 to 85 years with osteoporosis, defined as a femoral neck or lumbar spine bone mineral density T-score less than or equal to -2.5 or a vertebral fracture, and women with low bone mass, defined as a bone density T-score less than or equal to -1.0 and above -2.5, were assigned to arzoxifene 20 mg or placebo daily. The primary endpoints were new vertebral fracture in those with osteoporosis, and invasive breast cancer in the overall population. RESULTS: After 3 years, the cumulative incidence of vertebral fractures in patients with osteoporosis was 2.3% lower in the arzoxifene than in the placebo group, a 41% relative risk reduction (95% CI 0.45 to 0.77; P<0.001). In the overall population, the cumulative incidence of invasive breast cancer over 4 years was reduced by 1.3%, with a 56% relative reduction in risk (HR=0.44; 95% CI 0.26 to 0.76; P<0.001); there was no significant decrease in nonvertebral fracture risk. Arzoxifene increased the cumulative incidence of venous thromboembolic events by 0.7%, with a 2.3-fold relative increase (95% CI 1.5 to 3.7). CONCLUSION: Like other SERMs, arzoxifene decreased vertebral fractures and invasive breast cancer while the risk of venous thromboembolic events increased. (c) 2010 American Society for Bone and Mineral Research. [less ▲]

Detailed reference viewed: 14 (2 ULg)
Full Text
Peer Reviewed
See detailMarkers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards
Vasikaran, S.; Eastell, R.; Bruyère, Olivier ULg et al

in Osteoporosis International (2011), 22

Summary The International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) recommend that a marker of bone formation (serum procollagen ... [more ▼]

Summary The International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) recommend that a marker of bone formation (serum procollagen type I N propeptide, s-PINP) and a marker of bone resorption (serum C-terminal telopeptide of type I collagen, s-CTX) are used as reference analytes for bone turnover markers in clinical studies. Introduction Bone turnover markers (BTM) predict fracture risk, and treatment-induced changes in specific markers account for a substantial proportion of fracture risk reduction. The aims of this report were to determine their clinical potential in the prediction of fracture risk and for monitoring the treatment of osteoporosis and to set an appropriate research agenda. Methods Evidence from prospective studies was gathered through literature review of the PUBMED database between the years 2000 and 2010 and the systematic review of the Agency for Healthcare Research and Quality up to 2001. Results High levels of BTMs may predict fracture risk independently from bone mineral density in postmenopausal women. They have been used for this purpose in clinical practice for many years, but there is still a need for stronger evidence on which to base practice. BTMs provide pharmacodynamic information on the response to osteoporosis treatment, and as a result, they are widely used for monitoring treatment in the individual. However, their clinical value for monitoring is limited by inadequate appreciation of the sources of variability, by limited data for comparison of treatments using the same BTM and by inadequate quality control. IOF/IFCC recommend one bone formation marker (s-PINP) and one bone resorption marker (s-CTX) to be used as reference markers and measured by standardised assays in observational and intervention studies in order to compare the performance of alternatives and to enlarge the international experience of the application of markers to clinical medicine. Conclusion BTM hold promise in fracture risk prediction and for monitoring treatment. Uncertainties over their clinical use can be in part resolved by adopting international reference standards. [less ▲]

Detailed reference viewed: 59 (8 ULg)
Full Text
Peer Reviewed
See detailEffects of arzoxifene on fracture incidence in postmenopausal women with osteoporosis or with low bone mass
Reginster, Jean-Yves ULg; McClung, M.; Cox, D. et al

in Osteoporosis International (2010, May), 21(Suppl.1), 23-24

Detailed reference viewed: 20 (0 ULg)
Full Text
Peer Reviewed
See detailOral monthly ibandronate: rationale and clinical potential in postmenopausal osteoporosis
Reginster, Jean-Yves ULg; McClung, M.; Coutant, K. et al

in Annals of the Rheumatic Diseases (2003, June)

Detailed reference viewed: 24 (11 ULg)
Full Text
Peer Reviewed
See detailThe effect of risedronate on hip fracture risk in elderly women with osteoporosis
Bensen, W; Eastell, R; Reginster, Jean-Yves ULg et al

in Journal of Rheumatology (2001), 28(S63), 24

Detailed reference viewed: 2 (1 ULg)
Full Text
Peer Reviewed
See detailRapid and sustained hip fracture risk reduction with risedronate in elderly women with osteoporosis
Cooper, C; Reginster, Jean-Yves ULg; McClung, M et al

in BONE (2001), S28

Detailed reference viewed: 23 (1 ULg)
Full Text
Peer Reviewed
See detailRisedronate reduces hip fracture risk in elderly women with osteoporosis
McClung, M; Eastell, R; Bensen, W et al

in Osteoporosis International (2000), 11(S2), 207

Detailed reference viewed: 8 (1 ULg)
Full Text
Peer Reviewed
See detailRapid and sustained effects of risedronate in reducting hip fracture risk in elderly women with osteoporis
Seeman, E; McClung, M; Zippel, H et al

in Journal of Bone and Mineral Research (2000), 15(S1), 149

Detailed reference viewed: 5 (1 ULg)
Peer Reviewed
See detailRisedronate is well-tolerated in women with osteoporosis
McClung, M; Eastell, R; Watts, N et al

in Journal of Bone and Mineral Research (1999), 14(S1), 538

Detailed reference viewed: 5 (1 ULg)
Full Text
Peer Reviewed
See detailRisedronate reduces hip fractures in patients with low femoral neck bone mineral density
Miller, P; Roux, C; McClung, M et al

in Arthritis and Rheumatism (1999), 42(S1), 287

Detailed reference viewed: 6 (2 ULg)